See more : Nuformix plc (NFX.L) Income Statement Analysis – Financial Results
Complete financial analysis of CorMedix Inc. (CRMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CorMedix Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Winfull Group Holdings Limited (0183.HK) Income Statement Analysis – Financial Results
- Minth Group Limited (MNTHY) Income Statement Analysis – Financial Results
- Checkpoint Trends Limited (CHECKPOINT.BO) Income Statement Analysis – Financial Results
- tonies SE (TNIE.DE) Income Statement Analysis – Financial Results
- PennyMac Financial Services, Inc. (PFSI) Income Statement Analysis – Financial Results
CorMedix Inc. (CRMD)
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 65.41K | 190.94K | 239.23K | 283.27K | 429.80K | 329.33K | 224.11K | 210.13K | 189.27K | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 205.56K | 3.73K | 148.94K | 204.85K | 373.23K | 396.79K | 114.96K | 366.67K | 318.72K | 445.80K | 201.61K | 0.00 | 0.00 | 0.00 | 0.00 | 1.04M |
| Gross Profit | -205.56K | 61.67K | 42.00K | 34.39K | -89.97K | 33.01K | 214.36K | -142.57K | -108.59K | -256.53K | -199.60K | 0.00 | 0.00 | 0.00 | 0.00 | -1.04M |
| Gross Profit Ratio | 0.00% | 94.29% | 22.00% | 14.37% | -31.76% | 7.68% | 65.09% | -63.62% | -51.68% | -135.53% | -9,975.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.16M | 10.68M | 13.13M | 13.38M | 11.05M | 18.82M | 24.49M | 15.74M | 6.28M | 1.32M | 1.23M | 1.19M | 4.10M | 5.49M | 4.89M | 3.08M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.07M | 8.65M | 8.88M | 10.26M | 7.33M | 3.49M | 1.86M | 3.15M | 3.01M | 1.17M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.80M | 20.01M | 16.35M | 13.88M | 9.87M | 8.07M | 8.65M | 8.88M | 10.26M | 7.33M | 3.49M | 1.86M | 3.15M | 3.01M | 1.17M | 691.89K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.96M | 30.69M | 29.48M | 27.26M | 20.92M | 26.90M | 33.14M | 24.62M | 16.55M | 8.65M | 4.72M | 3.04M | 7.25M | 8.51M | 6.06M | 3.77M |
| Cost & Expenses | 48.96M | 30.69M | 29.48M | 27.46M | 21.29M | 27.29M | 33.25M | 24.99M | 16.86M | 9.09M | 4.92M | 3.04M | 7.25M | 8.51M | 6.06M | 4.82M |
| Interest Income | 0.00 | 326.02K | 14.40K | 116.07K | 322.67K | 36.62K | 110.71K | 126.77K | 60.39K | 2.71K | 668.00 | 1.97K | 12.04K | 23.44K | 2.13K | 25.90K |
| Interest Expense | 0.00 | 26.52K | 15.94K | 33.23K | 787.49K | 1.87K | 5.62K | 1.31K | 3.96K | 2.09K | 1.44M | 382.94K | 12.04K | 3.09M | 2.07M | 4.21M |
| Depreciation & Amortization | 70.76K | 209.04K | 177.02K | 143.49K | 73.29K | 74.22K | 36.89K | 25.60K | 15.08K | 15.07K | 5.16K | 7.02K | 12.25K | 12.17K | 9.95K | 1.04M |
| EBITDA | -48.89M | -30.05M | -29.38M | -27.02M | -20.63M | -26.75M | -32.97M | -24.62M | -18.17M | -20.44M | -7.68M | -3.04M | -7.19M | -8.47M | -6.04M | -3.75M |
| EBITDA Ratio | 0.00% | -46,321.48% | -15,421.12% | -11,329.92% | -7,302.40% | -6,241.92% | -9,963.77% | -10,980.81% | -7,889.64% | -4,693.90% | -245,581.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -48.96M | -30.62M | -29.44M | -27.22M | -21.01M | -26.86M | -32.92M | -24.76M | -16.65M | -8.90M | -4.92M | -3.04M | -7.25M | -8.51M | -6.06M | -4.82M |
| Operating Income Ratio | 0.00% | -46,819.91% | -15,417.51% | -11,378.44% | -7,416.31% | -6,250.44% | -9,997.39% | -11,048.80% | -7,925.56% | -4,703.30% | -245,646.93% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.62M | 336.65K | -22.83K | 23.67K | -485.98K | 34.57K | -85.80K | 117.29K | -1.53M | -11.55M | -4.22M | -380.97K | 41.86K | -2.68M | -2.07M | -4.18M |
| Income Before Tax | -46.34M | -30.29M | -29.46M | -27.20M | -21.49M | -26.83M | -33.01M | -24.64M | -18.19M | -20.45M | -9.13M | -3.43M | -7.21M | -11.19M | -8.12M | -9.00M |
| Income Before Tax Ratio | 0.00% | -46,305.23% | -15,429.47% | -11,368.54% | -7,587.87% | -6,242.40% | -10,023.45% | -10,996.46% | -8,655.37% | -10,806.25% | -456,426.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -585.62K | -1.25M | -5.17M | -5.06M | 36.44K | -31.27K | 1.31K | 3.96K | 2.09K | 1.44M | 1.97K | -493.86K | -280.92K | 2.13K | 0.00 |
| Net Income | -46.34M | -29.70M | -28.21M | -22.03M | -16.43M | -26.83M | -33.01M | -24.64M | -18.19M | -20.45M | -9.13M | -3.43M | -6.71M | -10.91M | -8.12M | -9.00M |
| Net Income Ratio | 0.00% | -45,409.90% | -14,774.70% | -9,207.70% | -5,801.29% | -6,242.40% | -10,023.45% | -10,996.46% | -8,655.37% | -10,806.25% | -456,426.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.91 | -0.74 | -0.75 | -0.77 | -0.68 | -1.51 | -2.99 | -3.25 | -2.90 | -4.77 | -3.30 | -1.50 | -2.94 | -5.76 | -47.40 | -3.94 |
| EPS Diluted | -0.91 | -0.74 | -0.75 | -0.77 | -0.68 | -1.51 | -2.99 | -3.25 | -2.90 | -4.77 | -3.30 | -1.50 | -2.94 | -5.76 | -47.40 | -3.94 |
| Weighted Avg Shares Out | 50.90M | 40.14M | 37.61M | 28.56M | 24.15M | 17.82M | 11.03M | 7.59M | 6.27M | 4.29M | 2.76M | 2.28M | 2.28M | 1.89M | 171.33K | 2.28M |
| Weighted Avg Shares Out (Dil) | 50.90M | 40.27M | 37.67M | 28.56M | 24.15M | 17.82M | 11.03M | 7.59M | 6.27M | 4.29M | 2.76M | 2.28M | 2.28M | 1.89M | 171.33K | 2.28M |
CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference
BERKELEY HEIGHTS, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that an abstract has been...
CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
BERKELEY HEIGHTS, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be giving...
CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology
BERKELEY HEIGHTS, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the publication of its Phase...
CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference
BERKELEY HEIGHTS, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be giving...
CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath
BERKELEY HEIGHTS, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the United States Patent...
CorMedix Inc. (CRMD) Q2 2023 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Daniel Ferry - LifeSci Advisors Joseph Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Phoebe Mounts...
CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update
BERKELEY HEIGHTS, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the second...
Why Shares of CorMedix Are Slumping Thursday
CorMedix's lead therapy is DefenCath. The company is awaiting word from the FDA on the therapy's approval.
Why Is Cormedix (CRMD) Stock Down 23% Today?
Cormedix (NASDAQ: CRMD ) stock is falling hard on Thursday after the company priced a public offering of its shares. That public offering has the company selling 7.5 million shares of CRMD stock at a price of $4 per share.
CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants
BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the pricing of its previously...
Source: https://incomestatements.info
Category: Stock Reports